Remove Analysis Remove BioTech Remove Life Science Remove Medicare
article thumbnail

The Healthcare and Macro-Economic Impacts of Living with Endemic COVID – Listening to Fitch

Health Populi

We also expect innovation to come out of pharma and biotech labs, and who will pay for new-new therapies? For Medicare Part B programs alone, the drug could consume one-half of the total $57 billion of medicines spending… as much as the U.S. spends on NASA.

BioTech 270
article thumbnail

Pharma – 2023 Health IT Predictions

Healthcare IT Today

Jesse Cugliotta, Global Industry GTM Lead, Healthcare & Life Sciences at Snowflake. Patient insight management will be a key strategic pillar: Life science organizations are more confident in the business value of insights management and are increasingly willing to commit the necessary technological resources to support this need.

article thumbnail

Most Americans Across Party ID Favor U.S. Government Negotiation to Lower Rx Drug Costs

Health Populi

is prescription drug prices — that they’re too high, that the Federal government should negotiate to lower costs for Medicare enrollees, and that out-of-pocket costs for drugs should be limited. One of the only issues bringing people together in the U.S. “Humalog isn’t thirteen times as effective as it used to be.